| Literature DB >> 31769344 |
Jiwon Oh1, Katayoun Alikhani2, Tania Bruno3, Virginia Devonshire4, Paul S Giacomini5, Fabrizio Giuliani6, Hamid R Nakhaipour7, Robyn Schecter7, Catherine Larochelle8.
Abstract
Identifying the transition of relapsing-remitting multiple sclerosis (MS) to the secondary-progressive MS form remains a clinical challenge due to the gradual nature of the transition, superimposed relapses, the heterogeneous course of disease among patients and the absence of validated biomarkers and diagnostic tools. The uncertainty associated with the transition makes clinical care challenging for both patients and physicians. The emergence of new disease-modifying treatments for progressive MS and the increasing emphasis of nonpharmacological strategies mark a new era in the treatment of progressive MS. This article summarizes challenges in diagnosis and management, discusses novel treatment strategies and highlights the importance of establishing a clear diagnosis and instituting an interdisciplinary management plan in the care of patients with progressive MS.Entities:
Keywords: biomarkers; disease-modifying therapy; inflammation; neuroprotective; secondary-progressive multiple sclerosis
Mesh:
Substances:
Year: 2019 PMID: 31769344 DOI: 10.2217/nmt-2019-0024
Source DB: PubMed Journal: Neurodegener Dis Manag ISSN: 1758-2024